Azurity Pharmaceuticals, Inc. drugs

24 results
  • azmiro

    (TESTOSTERONE CYPIONATE)
    Azurity Pharmaceuticals, Inc.
    AZMIRO is indicated for testosterone replacement therapy in males with conditions causing testosterone deficiency, including primary hypogonadism (e.g., testicular failure, Klinefelter’s syndrome) and hypogonadotropic hypogonadism (e.g., pituitary-hypothalamic injury). The safety and efficacy for age-related hypogonadism and pediatric patients under 12 are not established.
  • edarbi

    (Azilsartan kamedoxomil)
    Azurity Pharmaceuticals, Inc.
    Edarbi is indicated for treating hypertension in adults to lower blood pressure, thereby reducing the risk of cardiovascular events such as strokes and myocardial infarctions. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.
  • epaned

    (enalapril maleate)
    Azurity Pharmaceuticals, Inc.
    EPANED is indicated for treating hypertension in adults and children over one month, improving cardiovascular outcomes. It is also indicated for symptomatic heart failure, often with diuretics and digitalis, enhancing survival and reducing hospitalizations, and for asymptomatic left ventricular dysfunction, decreasing progression to overt heart failure.
  • fleqsuvy

    (baclofen)
    Azurity Pharmaceuticals, Inc.
    FLEQSUVY is indicated for treating spasticity due to multiple sclerosis, relieving flexor spasms, pain, clonus, and muscular rigidity. It may also benefit patients with spinal cord injuries or diseases, but is not intended for skeletal muscle spasms from rheumatic disorders.
  • katerzia

    (Amlodipine)
    Azurity Pharmaceuticals, Inc.
    KATERZIA is indicated for treating hypertension in adults and children (6+ years) to lower blood pressure, thus reducing cardiovascular event risks. It is also used for symptomatic treatment of chronic stable angina, vasospastic angina, and to decrease hospitalization and revascularization risk in patients with documented coronary artery disease.